‘Gene Therapy Market Set To Grow At A Cagr Of 41.1% In The First Half Of The Forecast Period’ says Visiongain

27 July 2018
Pharma

Visiongain’ has launched a new pharma report Gene Therapy R&D and Revenue Forecasts 2018-2028: Prospects for Drugs Treating Cancer, Cardiovascular Disorders, Rare Diseases, Ophthalmologic Conditions, Other Diseases, Approved Gene therapies, R&D Pipeline Analysis, Gene Therapy Regulations by Region and Leading Players

The gene therapy market is still establishing itself and many opportunities are available to explore at the moment. One opportunity in this market is for smaller biotechnology companies, which because of their size and infrastructure may be able to develop an orphan drug quicker than a Big Pharma company can. Another opportunity in the gene therapy market is the development of novel technologies such as CRISPR (clustered regularly interspaced short palindromic repeats). Gene therapy has seen many advances in recent years, such as improvement in viral vector delivery for safe and efficacious gene delivery and expression.

The lead analyst of the report commented “The growth of the overall gene therapy market will be driven by the immense pipeline of gene therapies in development. Many gene therapies in development target orphan diseases with high unmet need, this pipeline includes therapies that cover a wide range of indications for the cancer, cardiovascular, ophthalmologic, rare diseases, musculoskeletal, neurodegenerative and metabolic disease submarkets among others.

Clinical trials so far have demonstrated favourable results in a broad range of indications with treatments predicted to launch in the next few years for the cardiovascular disease, rare disease, and cancer submarkets.”

Leading companies featured in the report include UniQure, Biogen, Bluebird Bio, Spark Therapeutics, Applied Genetics Technologies Corporation, Oxford Biomedica, GenSight Biologics and other leading companies currently developing gene therapies. Leading Big Pharma Companies mentioned in this report include Bristol-Myers Squibb, Pfizer, Bayer, Novartis, Roche, Sanofi & GSK.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Top 25 Vaccines market set to grow to $41bn by 2024” says new Visiongain report

There is an increasing focus to identify diseases that currently do not have a vaccine.

20 June 2019

Read

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever